Analyst Group

Analyst Group Comment on Pharma Equity Group’s Letter of Intent to Acquire MedTech Company Otiom A/S

Källa: MFN
Neutral

Sammanfattning

Pharma Equity Group (PEG) har ingått ett Letter of Intent (LOI) för att förvärva antingen hela aktiekapitalet eller en majoritetsandel i det danska MedTech-bolaget Otiom A/S. Transaktionen är det första steget i PEGs strategi att bygga en diversifierad Life Science-portfölj.

Analys

LOI är inte ett bindande avtal. Detta är ett tidigt skede och det finns ingen garanti för att förvärvet kommer att slutföras. Det är en indikation på PEGs strategiska ambitioner att expandera inom Life Science-sektorn, men det konkreta värdet och effekten på aktieägarna är ännu okänt.

Pharma Equity Group (“PEG” or “the Company”) announced on Wednesday, December the 10th 2025, that the Company has entered into a Letter of Intent (LOI) to acquire either the entire share capital or a majority stake in the Danish MedTech company Otiom A/S (“Otiom”). The transaction represents the first concrete step in executing the Company’s expanded strategy: to build a diversified Life Science portfolio spanning Pharma, MedTech, and related health technologies.

Pharma Equity Group (“PEG” or “the Company”) announced on Wednesday, December the 10th 2025, that the Company has entered into a Letter of Intent (LOI) to acquire either the entire share capital or a majority stake in the Danish MedTech company Otiom A/S (“Otiom”). The transaction represents the first concrete step in executing the Company’s expanded strategy: to build a diversified Life Science portfolio spanning Pharma, MedTech, and related health technologies.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Pharma Equity Group. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.